Network origin in Laura Barrow first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 24 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Laura Barrow via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Advent International LP
 Advent International LP Investment ManagersFinance Advent International LP (Advent) is an independent private equity firm founded in 1984 by Henry H. Haight. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
| ENZON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO Director/Board Member | |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
OraPharma, Inc.
 OraPharma, Inc. Pharmaceuticals: MajorHealth Technology OraPharma, Inc. develops and produces drugs for oral diseases. It offers a suite of products to address a range of patient concerns from the foundation of gums, bone, and teeth to the aesthetics of a whiter smile. The company's products include ARESTIN Microspheres, a locally administered antibiotic indicated as an adjunct to scaling and root planning procedures for the reduction of pocket depth in patients with adult periodontitis; and ONSET Approach, a unique delivery system of locally buffered anesthesia that provides faster onset of anesthesia and a comfortable injection. The company was founded in 1996 and is headquartered in Horsham, PA. | Pharmaceuticals: Major | Founder Chief Executive Officer General Counsel Chief Operating Officer Comptroller/Controller/Auditor | |
| EXELIXIS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| ESPERION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Founder | |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Pharmaceuticals: Major | Director/Board Member | |
Pulmatrix Operating Co., Inc.
 Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | Pharmaceuticals: Major | Director/Board Member | |
| MARINUS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman General Counsel | |
| RADIUS HEALTH, INC. | Biotechnology | Chairman | |
Cellzome Ltd.
 Cellzome Ltd. Pharmaceuticals: MajorHealth Technology Cellzome Ltd. engages in the research, development, and manufacture of pharmaceutical products. It provides kinase-targeted drugs to treat inflammatory diseases. The company was founded by Gitte Neubauer on December 22, 2003 and is headquartered in Middlesex, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder Director/Board Member | |
| University of Pennsylvania | College/University | Doctorate Degree Undergraduate Degree | |
Astra Merck, Inc.
 Astra Merck, Inc. Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, Astra Merck, Inc. is a company that sells pharmaceutical products. The company is based in Orlando, FL. The company was founded by Myrtle S. Potter, Thomas A. McCourt. Astra Merck was acquired by Astra AB from Merck & Co., Inc. on July 12, 1998 for $4,400 million. | Pharmaceuticals: Major | Director/Board Member | |
| ZOETIS INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Hillsdale College | College/University | Undergraduate Degree | |
| King's College (Pennsylvania) | College/University | Undergraduate Degree | |
| Yale University | College/University | Corporate Officer/Principal Undergraduate Degree Undergraduate Degree | |
| St. Joseph's University | College/University | Masters Business Admin Masters Business Admin | |
Lev Pharmaceuticals, Inc.
 Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lev Pharmaceuticals, Inc. develops and commercializes therapeutic products for the treatment of inflammatory diseases. It researches a series of drugs to fight both edema and heart attacks. The company is located in New York. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Biotechnology | Chief Executive Officer | |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Sales & Marketing Director/Board Member | |
White Cube Management LLC
 White Cube Management LLC Miscellaneous Commercial ServicesCommercial Services White Cube Management LLC provides management services. The private company is based in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Spear Therapeutics Ltd.
 Spear Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Spear Therapeutics Ltd. develops cancer treatment drugs. The firm offers cytochrome P450 (CYP)-activated prodrugs. It designs prodrugs that are activated by enzymes that are found in cancer tissues. The company was founded by Steven A. Everett and Gerard Andrew Potter and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Synthesis Capital
 Synthesis Capital Investment ManagersFinance Synthesis Capital is a venture capital firm founded in 2007. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Chief Executive Officer | |
| Alevium Pharmaceuticals, Inc. | Director/Board Member | ||
| UNIQURE N.V. | Biotechnology | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| SERES THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| The Leonard N Stern School of Business | College/University | Undergraduate Degree Undergraduate Degree | |
| PULMATRIX, INC. | Pharmaceuticals: Major | Director/Board Member | |
DiNAQOR AG
 DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Biotechnology | Director/Board Member | |
IEcure, Inc.
 IEcure, Inc. BiotechnologyHealth Technology iECURE, Inc. is a gene editing company that focuses on developing therapies for liver disorders with significant unmet need. The company is based in Plymouth Meeting, PA, and the CEO of the company is Joseph Truitt. The company's approach involves mutation-agnostic in vivo gene insertion or knock-in editing, which has the potential to replace and restore the function of a dysfunctional gene, regardless of mutation. iECURE collaborates with the University of Pennsylvania's Gene Therapy Program to utilize their translational expertise and infrastructure. The company's management team has extensive experience in executing orphan drug and gene therapy clinical trials and successfully commercializing multiple products. iECURE's programs are currently focused on developing in vivo gene insertion therapies for the treatment of rare pediatric liver diseases. | Biotechnology | Chief Executive Officer Chief Operating Officer |
Statistics
International
| United States | 44 |
| Netherlands | 3 |
| United Kingdom | 3 |
| Israel | 2 |
| Germany | 2 |
Sectoral
| Health Technology | 33 |
| Consumer Services | 8 |
| Commercial Services | 5 |
| Finance | 3 |
| Distribution Services | 2 |
Operational
| Director/Board Member | 114 |
| Corporate Officer/Principal | 48 |
| Independent Dir/Board Member | 33 |
| Chairman | 22 |
| Undergraduate Degree | 18 |
Most connected contacts
| Insiders | |
|---|---|
| Jason S. Fisherman | 30 |
| Nicole Vitullo | 29 |
| Robert van Nostrand | 22 |
| David I. Scheer | 19 |
| Frank Verwiel | 16 |
| Kurt Graves | 15 |
| Martha Manning | 13 |
| Steven Zelenkofske | 13 |
| Anthony Gibney | 11 |
| Michael Kishbauch | 10 |
| Mary Fenton | 10 |
| Joseph Truitt | 10 |
| Paul Firuta | 10 |
| Douglas John Barry | 10 |
| Aradhana Sarin | 9 |
- Stock Market
- Insiders
- Laura Barrow
- Company connections
